Andrea Anichini spends much of her time researching Immunology, Cancer research, Antigen, Cytotoxic T cell and Melanoma. Andrea Anichini focuses mostly in the field of Cancer research, narrowing it down to matters related to Mutation and, in some cases, Carcinogenesis, Oncogene and Receptor. In Antigen, Andrea Anichini works on issues like Immunotherapy, which are connected to Immunogenicity, Monoclonal, Phases of clinical research and Cisplatin.
Her Cytotoxic T cell research is multidisciplinary, incorporating elements of Melanocyte differentiation and CD3. The various areas that Andrea Anichini examines in her Melanoma study include Monoclonal antibody and Pathology. Her research in CTL* focuses on subjects like Molecular biology, which are connected to HLA-A2 Antigen and Clone.
Her primary scientific interests are in Cancer research, Immunology, Melanoma, Cytotoxic T cell and Antigen. Her Cancer research research is multidisciplinary, incorporating perspectives in Apoptosis, Programmed cell death, Receptor tyrosine kinase and Oncogene. T cell, CD8, Immune system, T-cell receptor and Immunotherapy are among the areas of Immunology where the researcher is concentrating her efforts.
Her study in Immune system is interdisciplinary in nature, drawing from both Immunohistochemistry, Cancer and Internal medicine. Her studies examine the connections between Melanoma and genetics, as well as such issues in Integrin, with regards to Cell biology. The concepts of her Cytotoxic T cell study are interwoven with issues in Molecular biology, T lymphocyte and CD3.
Her scientific interests lie mostly in Cancer research, Pembrolizumab, Urology, Internal medicine and Immunotherapy. Andrea Anichini is studying Melanoma, which is a component of Cancer research. She works mostly in the field of Pembrolizumab, limiting it down to topics relating to Cystectomy and, in certain cases, Phases of clinical research and Cisplatin, as a part of the same area of interest.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology. Her Immunotherapy study which covers Tumor microenvironment that intersects with Gene regulatory network, Computational biology, Gene and Gene signature. Her Antigen research includes elements of Cytotoxic T cell and Monoclonal antibody.
Her primary areas of study are Cancer research, Melanoma, Immunotherapy, Immunohistochemistry and Immune system. Andrea Anichini combines subjects such as Semaphorin, Cell migration, Lung cancer, Antibody and Gene silencing with her study of Cancer research. Her Antibody research incorporates elements of Cancer cell, Cytotoxic T cell, CD3 and Antigen.
Her Melanoma study combines topics from a wide range of disciplines, such as Apoptosis, Transcription factor, Metastasis and Blot. Her studies deal with areas such as Cystectomy, Carcinoma and Urology as well as Immunotherapy. Her Immune system research includes themes of Cancer therapy, Disease and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano;Roberta Frapolli;Cristina Belgiovine;Achille Anselmo.
Cancer Cell (2013)
Interleukin-12: biological properties and clinical application.
Michele Del Vecchio;Emilio Bajetta;Stefania Canova;Michael T. Lotze.
Clinical Cancer Research (2007)
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Giorgio Parmiani;Chiara Castelli;Piero Dalerba;Roberta Mortarini.
Journal of the National Cancer Institute (2002)
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study
Andrea Necchi;Andrea Anichini;Daniele Raggi;Alberto Briganti.
Journal of Clinical Oncology (2018)
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
Tadepally Lakshmikanth;Shannon Burke;Talib Hassan Ali;Silvia Kimpfler.
Journal of Clinical Investigation (2009)
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Licia Rivoltini;Matteo Carrabba;Veronica Huber;Chiara Castelli.
Immunological Reviews (2002)
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.
S. Siena;M. Di Nicola;M. Bregni;R. Mortarini.
Experimental Hematology (1995)
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo;Massimo Moro;Michele Sommariva;Valeria Cancila.
Clinical Cancer Research (2019)
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients
Andrea Anichini;Cristina Maccalli;Roberta Mortarini;Stefania Salvi.
Journal of Experimental Medicine (1993)
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
A Anichini;A Molla;R Mortarini;G Tragni.
Journal of Experimental Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: